The grant funds early-stage academic research with no near-term revenue or regulatory catalyst. Monitor for enrollment updates and any future partnership or licensing terms, but this does not change RedHill's near-term cash runway or commercial outlook.
Price Chart
Executive Summary
RedHill's partner, the University of Oklahoma, received a $2.9 million NCI grant to fund Phase 1b/2 clinical trials of opaganib combined with CAR T-cell therapy in ultra-high-risk multiple myeloma. The grant is a non-dilutive, academic-led funding source that supports early-stage research, but the trials are years from generating pivotal data and opaganib remains an investigational drug with no near-term commercial path.
Key Financial Metrics
Key Facts
- NCI awarded a $2.9 million, five-year grant to the University of Oklahoma for clinical trials of opaganib + CAR T-cell therapy in ultra-high-risk multiple myeloma.
- Phase 1b plans to enroll up to 18 patients; Phase 2 plans up to 21 additional patients.
- RedHill will provide opaganib; Lentigen Technology (Miltenyi Biotec) developed the CAR construct.
- Opaganib is an investigational drug not approved for any indication; the grant is non-dilutive to RedHill.
Financial Impact
$2.9 million NCI grant to the University of Oklahoma; no direct revenue or cost to RedHill stated.
Risk Factors
- Clinical trials may fail to demonstrate safety or efficacy; opaganib has no approved oncology indication.
- NCI funding could be reduced, delayed, or terminated due to government funding uncertainty.
- RedHill's ability to maintain Nasdaq listing and secure additional financing remains a concern given recent capital raises.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302912502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4160 (−8.57%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4160 (−17.00%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4160 (−17.00%) |
Oct 13, 2026 13d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4160 (+14.44%) |
Oct 13, 2026 13d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4160 (+14.44%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4160 (−12.24%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4160 (−52.18%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4160 (−53.78%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4160 (−31.24%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4160 (−28.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers